Achilles Therapeutics Ltd., of Stevenage, U.K., appointed Beverley Carr chief business officer, effective Nov. 4.
Akcea Therapeutics Inc., of Boston, appointed Kyle Jenne chief commercial officer.
Amgen Inc., of Thousand Oaks, Calif., appointed Peter H. Griffith executive vice president, finance. He will become chief financial officer Jan. 1, 2020.
Blackthorn Therapeutics Inc., of San Francisco, appointed William J. Martin CEO and to its board.
Cedilla Therapeutics Inc., of Cambridge, Mass., appointed Justin Birtz vice president, people and culture.
Cohbar Inc., of Menlo Park, Calif., appointed Misha Petkevich to its board.
Dariohealth Corp., of New York, appointed Abigail Hirsch to its advisory board.
Eli Lilly and Co., of Indianapolis, appointed Mike Mason senior vice president of Lilly and president of Lilly Diabetes.
Essa Pharma Inc., of Vancouver, British Columbia, appointed Ari Brettman to its board.
Galimedix Therapeutics Inc., of Kensington, Md., appointed Alexander Gebauer executive chair of its board.
Heparegenix GmbH, of Tubingen, Germany, appointed Michael Lutz CEO and managing director.
Impel Neuropharma Inc., of Seattle, appointed Diane Wilfong to its board.
Kiadis Pharma NV, of Amsterdam, appointed Chiara Bonini, Michael Caligiuri, Todd Fehniger, Helen Heslop, Carl June, Krishna Komanduri, Elaine Mardis and Dean Lee to its scientific advisory board.
Kintai Therapeutics Inc., of Cambridge, Mass., appointed Francesca Barone head of experimental medicine.
Lifemine Therapeutics Inc., of Boston, appointed Iain McFadyen chief data officer, Jared Cumming senior vice president and head of chemistry and Dawn Thomspon vice president and head of microbiology and automation.
Maze Therapeutics Inc., of South San Francisco, appointed Jonathan Lim to its board.
Ocugen Inc., of Malvern, Pa., appointed Jessica Crespo controller.
On Target Laboratories Inc., of West Lafayette, Ind., appointed Kimberly Fabrizio vice president of regulatory and quality.
Quotient Sciences Ltd., of Nottingham, U.K., appointed Claes Glassell non-executive chair of its board.
Reviral Ltd., of London, appointed Alan A. Musso chief financial officer.
Rheos Medicines Inc., of Cambridge, Mass., appointed Barbara S. Fox CEO.
Scancell Holdings plc, of Nottingham, U.K., appointed Ursula Ney to its board.
Senti Biosciences Inc., of South San Francisco, appointed Brenda Cooperstone to its board.
Sirona Biochem Corp., of Vancouver, British Columbia, appointed Pinqiao Zhao as a consultant.
Smartpharm Therapeutics Inc., of Cambridge, Mass., appointed John T. Potts to its board.
Stalicla SA, of Geneva, appointed Stéphane Baudouin chief of science.
Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan, appointed Shigeyuki Nishinaka executive officer global business development and international business management senior director, global business development.
Taiwan Liposome Co. Ltd. (TLC), of Taipei, Taiwan, appointed Vincent Chang vice president of manufacturing development.